A phase I open-label dose-escalation study to investigate the safety pharmacokinetics pharmacodynamics and clinical activity of GSK3368715 in participants with solid tumors and DLBCL
Brief description of study
The purpose of this study is to test the safety, tolerability, and effectiveness of GSK3368715 (called the study drug from now on) for solid tumors and DLBCL. We want to find out what effects, good or bad, the study drug has on you and your cancer. This is an investigational study of a drug named GSK3368715, which means it is still being tested and is not approved by the US Food and Drug Administration (FDA) as a routine therapy.
Clinical Study Identifier: s18-00837
ClinicalTrials.gov Identifier: NCT03666988
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
